The MarketWatch News Department was not involved in the creation of this content. -- This marks the first live procedure at AAHS, as well as a first for Keenova. -- Treatment takes place over two days ...
BioSpecifics Technologies announced positive results from its Phase 3b MULTICORD study evaluating Xiaflex (collagenase clostridium histolyticum) for the concurrent treatment of adult Dupuytren’s ...
DUBLIN, Jan. 14, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it will present a live treatment procedure with XIAFLEX ® (collagenase clostridium histolyticum) for Dupuytren's ...
This marks the first live procedure at AAHS, as well as a first for Keenova. Treatment takes place over two days of annual meeting—injection on Wednesday and finger extension on Friday. Audience of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results